Terns Pharmaceuticals 放弃口服 GLP-1,退出减重领域

Minhua笔记
Oct 23, 2025

去年,Terns Pharmaceuticals (中国子公司名:拓臻生物)的口服减重药项目早期数据引起轰动,但其未能在一项中期研究中复制这一成功。该公司表示,由于安全性担忧和减重效果不佳,将终止 GLP-1 激动剂 TERN-601 的开发,并且没有计划推进或投资其他代谢疾病药物。该公司在10月21日公布了 II 期 FALCON 试验的主要结果,该试验招募了 167 名 BMI 在 30 至 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10